Literature DB >> 25059444

Carbapenem and multidrug resistance in Gram-negative bacteria in a single centre in Italy: considerations on in vitro assay of active drugs.

Maria Lina Mezzatesta1, Carla Caio2, Floriana Gona3, Roberta Cormaci2, Iasmine Salerno2, Tiziana Zingali2, Carmelo Denaro4, Mauro Gennaro4, Cristiana Quattrone4, Stefania Stefani2.   

Abstract

In intensive care units (ICUs), the most important causes of nosocomial bacterial infections are mainly multidrug-resistant (MDR) and extensively drug-resistant (XDR) Acinetobacter baumannii and Klebsiella pneumoniae strains. Mortality related to these infections is very high due to lack of effective therapy and the severity of patient conditions. This study aimed to assess the prevalence of carbapenem resistance genes in 77 carbapenem-resistant Gram-negative bacteria isolated from severe infections (bloodstream, pulmonary and urinary tract) during the period 1 January to 31 July 2013 in a general ICU in Catania, Italy, and to examine their susceptibility to tigecycline and colistin using two different methods. In total, 52 A. baumannii belonging to the same sequence type (ST) 2 clone and carrying the bla(OXA-23) gene as well as 25 K. pneumoniae carrying bla(KPC-3) were isolated. Four distinct pulsotypes were identified in K. pneumoniae, which correlated with four distinct STs: ST258 and ST512, spread worldwide, and ST147 and ST395 detected for the first time in Italy. A. baumannii isolates showed an XDR profile and were fully susceptible only to colistin; all KPC-producing K. pneumoniae isolates were MDR, whilst colistin was active against 19 of 25 strains. These results show that broth microdilution (BMD) is a reliable in vitro susceptibility test for colistin, above all K. pneumoniae, whilst both the gradient test and BMD are suitable for tigecycline susceptibility testing of A. baumannii. Published by Elsevier B.V.

Entities:  

Keywords:  Acinetobacter baumannii; Carbapenemase; Colistin; Klebsiella pneumoniae; Tigecycline

Mesh:

Substances:

Year:  2014        PMID: 25059444     DOI: 10.1016/j.ijantimicag.2014.04.014

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  9 in total

Review 1.  Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.

Authors:  Laurent Poirel; Aurélie Jayol; Patrice Nordmann
Journal:  Clin Microbiol Rev       Date:  2017-04       Impact factor: 26.132

2.  Molecular epidemiology and characterization of multiple drug-resistant (MDR) clinical isolates of Acinetobacter baumannii.

Authors:  Sherief El-Shazly; Ali Dashti; Leila Vali; Michael Bolaris; Ashraf S Ibrahim
Journal:  Int J Infect Dis       Date:  2015-10-27       Impact factor: 3.623

3.  Characterization of Carbapenemases in Extensively Drug Resistance Acinetobacter baumannii in a Burn Care Center in Iran.

Authors:  Leila Azimi; Malihe Talebi; Mohammad-Reza Pourshafie; Parviz Owlia; Abdolaziz Rastegar Lari
Journal:  Int J Mol Cell Med       Date:  2015

Review 4.  Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.

Authors:  M J D Dautzenberg; M R Haverkate; M J M Bonten; M C J Bootsma
Journal:  BMJ Open       Date:  2016-03-17       Impact factor: 2.692

5.  Polyclonal Endemicity of Carbapenemase-Producing Klebsiella pneumoniae in ICUs of a Greek Tertiary Care Hospital.

Authors:  Efthymia Protonotariou; Georgios Meletis; Dimitrios Pilalas; Paraskevi Mantzana; Areti Tychala; Charalampos Kotzamanidis; Dimitra Papadopoulou; Theofilos Papadopoulos; Michalis Polemis; Simeon Metallidis; Lemonia Skoura
Journal:  Antibiotics (Basel)       Date:  2022-01-25

6.  In Vitro Activity of Sulbactam-Durlobactam against Carbapenem-Resistant Acinetobacter baumannii Clinical Isolates: A Multicentre Report from Italy.

Authors:  Bernardetta Segatore; Alessandra Piccirilli; Sabrina Cherubini; Luigi Principe; Giovanni Alloggia; Maria Lina Mezzatesta; Mario Salmeri; Stefano Di Bella; Roberta Migliavacca; Aurora Piazza; Elisa Meroni; Paolo Fazii; Daniela Visaggio; Paolo Visca; Venere Cortazzo; Giulia De Angelis; Arianna Pompilio; Mariagrazia Perilli
Journal:  Antibiotics (Basel)       Date:  2022-08-22

7.  Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii.

Authors:  Laurent Poirel; Mustafa Sadek; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2021-07-12       Impact factor: 5.191

8.  Diversity of multi-drug resistant Acinetobacter baumannii population in a major hospital in Kuwait.

Authors:  Leila Vali; Khadija Dashti; Andrés F Opazo-Capurro; Ali A Dashti; Khaled Al Obaid; Benjamin A Evans
Journal:  Front Microbiol       Date:  2015-07-23       Impact factor: 5.640

9.  Epidemiological evaluation of an Acinetobacter baumannii outbreak observed at an intensive care unit.

Authors:  Tuğba K Atik; Bülent Atik; Osman Kilinç; Bayhan Bektöre; Hülya Duran; Burak M Selek; Nihan Ceken; Orhan Baylan; Mustafa Özyurt
Journal:  Saudi Med J       Date:  2018-08       Impact factor: 1.484

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.